EATG » Gilead submits supplemental New Drug Application to FDA for once-daily Descovy® for PrEP

Gilead submits supplemental New Drug Application to FDA for once-daily Descovy® for PrEP

Gilead submits supplemental New Drug Application to U.S. Food and Drug Administration for once-daily Descovy® for HIV Pre-Exposure Prophylaxis

– Filing supported by data demonstrating non-inferiority compared to Truvada® coupled with bone and renal safety advantages in people at risk of sexually acquired HIV infection –

Read the full press release here.


 

Source:
Gilead Sciences, Inc.
News categories: EMA/FDA, PrEP